Overture Life Secures $57M in Total Funding and Earns U.S. CLIA License to Deliver Reliable, Scalable IVF Automation

Business Wire

24-04-2025

PALO ALTO, Calif.--(BUSINESS WIRE)--Overture Life today announced a $20.6 million strategic round, bringing its total funding to $57 million from leading industry investors, to support additional clinical research and product development designed to make IVF affordable to more people. The company is also announcing its newly achieved CLIA (Clinical Laboratory Improvement Amendments) license in the United States to meet federal clinical laboratory standards for m|z, its AI-powered, non-invasive metabolomic test for embryo selection. These latest milestones reinforce Overture's commitment to demonstrating scientific rigor, securing regulatory support, and prioritizing patient safety. They also pave the way for the launch of DaVitri, an advanced embryology platform that automates egg freezing (vitrification) and embryo warming under reproducible, data-driven protocols.
For too long, IVF has been inaccessible for too many people, with inefficiencies driving up costs. Since 2017, Overture has modernized the core technology involved in IVF through proprietary software, robotics, microfluidics and rigorous scientific validation, documented in peer-reviewed publications, scientific presentations, and, most importantly, two healthy, live births resulting from the use of its technology.
Its newest platform, DaVitri, addresses essential lab steps that historically rely on manual precision. By standardizing these procedures with precise timing and controlled cryoprotectant exposure, DaVitri has demonstrated improved oocyte survival rates in early clinical evaluations, potentially reducing repeated IVF cycles that can drain resources and emotional energy. In addition, its streamlined, gentler freezing process helps clinics maintain consistent lab results, allowing embryologists to handle more cycles without compromising quality.
'This new funding allows us to accelerate our expansion of IVF capabilities and demonstrates the value of operating within a CLIA-licensed laboratory environment, highlighting not only our technological leadership but also our commitment to the highest standards of clinical validation,' said Hans Gangeskar, CEO of Overture Life. 'DaVitri has already shown potential to significantly increase clinical throughput while ensuring reproducibility in critical freezing and warming processes, allowing embryologists to prioritize personalized patient care. Our approach is rigorous and evidence-based because we understand how deeply personal this journey is for families.'
'Automation and standardization in the embryology lab is an exciting step towards optimizing efficiency and efficacy in IVF. It allows us to deliver consistent and excellent care, while still giving us the flexibility to fine-tune protocols for our patients," said Serena H. Chen, MD, a Reproductive Endocrinologist at CCRM Fertility of NJ. 'We're very excited about the potential to serve more patients by increasing lab capacity without sacrificing quality.'
This strategic round, supported by Overwater Ventures, GV (formerly Google Ventures), and Khosla Ventures, reflects a deep conviction in Overture's science-led mission: to expand fertility access by making IVF labs more reproducible, efficient, and ultimately less cost-intensive.
'Fertility intersects healthcare, economics, and the most personal of human wishes,' said Kristina Simmons, Founder and Managing Partner at Overwater Ventures. 'Women have long faced irreversible biological timelines, and by making egg freezing cheaper, easier, and more clinically effective and predictable, it allows women and families to regain choice and opportunity. Overture's platform provides a precise alternative that can run more cycles successfully, enabling women to freeze their eggs or pursue IVF on their own terms and timelines. By fitting the embryology protocols into a compact, desk-sized system, Overture is reinventing egg freezing and IVF for a better patient experience and strong, clinically reproducible outcomes with proven science.'
Overture Life integrates engineering, reproductive medicine, and regulatory-grade validation to modernize embryology lab procedures, particularly egg freezing and embryo handling, in ways that lower repeated cycles, increase throughput, and reduce the overall cost of IVF. With R&D in Spain and active U.S. operations, including a CLIA-licensed laboratory for non-invasive embryo selection, Overture unites robotics, analytics, and clinical rigor to deliver tools that clinics and patients can trust. The company's DaVitri platform aims to boost reliability and consistency in IVF, giving women and families worldwide more control over their fertility timelines. Overture's backers include Overwater Ventures, GV, Khosla Ventures, Octopus Ventures and others committed to advancing the future of fertility.